Month: February 2007
-
By Kevin E. Noonan A state appeals court in San Francisco upheld the California Institute for Regenerative Medicine (CIRM), the result of passage (by a referendum vote of 59% of California voters) of Proposition 71 in 2004. The CIRM and California’s legal capacity to fund the Institute under Proposition 71 were challenged by…
-
By Kevin E. Noonan Five years ago, reports from the University of Minnesota promised to reconcile the budding science of human stem cell biology with the restrictive regulations the Bush administration had imposed on federally funded embryonic stem cell research. These reports indicated that adult stem cells, specifically hematopoietic stem cells that are…
-
By Sherri Oslick A note to our readers: Patent Docs apologizes to our readers for the recent Court Report hiatus. This Court Reporter was deeply immersed in very intensive preliminary injunction proceedings and has just now been able to come up for air. We will catch our readers up in the next few…
-
By Kevin E. Noonan Many have noted the recent trend in U.S. Supreme Court review, and disagreement with, Federal Circuit decisions. Indeed, only two Federal Circuit decisions have been affirmed by the Supreme Court since 1995. Some have questioned whether this level of negative review might tend to diminish the Federal Circuit’s role…
-
By Donald Zuhn An article at BusinessWeek.com ("Biotech IPO’s Iffy Prognosis") attributes a recent drop in initial public offerings (IPO’s) for small biotech companies to the reluctance of investors to forgo big paydays as small biotechs use much of the cash raised from such offerings on drug development. However, while the biotech IPO…
-
By Mark Chael GenTel BioSciences of Madison, Wisconsin recently announced that it had raised $1.5 million USD in angel financing for development and commercialization of protein chips and assays, plus $500,000 USD to be used to complete a new partnership with a large pharmaceutical company. However, other than the fact that the deal…
-
By Sherri Oslick A note to our readers: Patent Docs apologizes to our readers for the recent Court Report hiatus. This Court Reporter was deeply immersed in very intensive preliminary injunction proceedings and has just now been able to come up for air. We will catch our readers up in the next few…
-
By Kevin E. Noonan DNA has a unique status among biological molecules, being both a chemical and information comprising the nucleotide sequence that encodes the amino acid sequence of a gene’s cognate protein. In a recent article in Science, Michael Gottesman and his colleagues at the National Institutes of Health have demonstrated that…
-
February 27-28, 2007 – Patent Portfolio Management (American Conference Institute) – New York, NY March 21-22, 2007 – Complex IP & Technology Transactions Conference (Law Seminars International) – Chicago, IL March 25-29, 2007 – American Chemical Society National Meeting – Chicago, IL April 16-18, 2007 – Biotechnology: Patent Prosecution, Licensing, Litigation & Hatch-Waxman (Patent Resources…
-
By Kevin E. Noonan Earlier this week, the National Eye Institutes (NEI) of the National Institutes of Health announced that it would conduct a study comparing the effectiveness of two Genentech drugs, Lucentis® and Avastin®, for the treatment of age-related macular degeneration (AMD). This was not good news for Genentech, because although treating…
Patent Docs 